EIKON Group

https://www.eikon.group
https://www.linkedin.com/company/eikon-group/

EIKON Group, privately owned and headquartered in the UK, was founded in 2014 and employs approximately 210 individuals, having reported $25.7M in revenue as of 2024. The company specializes in media managed services, functioning as a provider for post-production, localisation, and mastering.

2024 Revenue

Founded

2014

Headcount

203

Headquarters

Primary Segment

Media managed services

Ownership

Privately Owned

Deployments

News Summary:

On February 6, 2026, Eikon's shares declined in the aftermarket, even though its initial public offering met or exceeded expectations, contributing to a mixed set of signals for biotech companies hoping 2026 would open the IPO window. Previously, on February 2, 2026, EIKON Group acquired Masterwords, a theatrical scripting service provider with a 40-year track record, to strengthen its global scripting capabilities for the media and entertainment industry, which includes localization, QC, mastering, and distribution. This acquisition followed Eikon's IPO filing on January 9, 2026, after the company raised more than $1 billion to develop cancer-fighting drugs and related tools. Eikon's leadership team includes a former research chief from two pharmaceutical giants, and its investor roster features prominent venture capital firms in life sciences.

Similar Companies

Subscribe for full access to EIKON Group's profile

EIKON Group offers 12 products in the media tech industry. EIKON Group's product portfolio comprises of production and post production, media managed services, content supply chain and media cloud and storage.

Subscribe for full access to EIKON Group's products in full detail

EIKON Group's revenues were less than $50M in 2024. Caretta Research has split EIKON Group's revenue into 10 different product categories, the largest of which is localisation and access services. For full access to EIKON Group's revenue breakdown subscribe to Caretta Portal.

Subscribe for full access to EIKON Group's revenue in full detail

Mar

13th

2026

18:03

B2B Tag

Client Challenge

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Eikon Group

Feb

6th

2026

18:26

Funding Activities, Capital Investment

Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report

ARTICLE | Finance All four life sciences companies that priced IPOs this week met or exceeded their expectations, although the two with more innovative products saw their share prices decline in the aftermarket. It’s a mixed set of signals for the long list of biotechs hoping 2026 will be the year when the IPO window opened up, after a few years of finding other sources of capital while waiting for market conditions to improve...

BioCentury

Feb

2nd

2026

10:30

EIKON Acquires Masterwords – EIKON

Strengthening Global Scripting Capabilities [Burbank, California], [02.02.2026] – EIKON Group, a leading global provider of technology-enabled content services, including localization, QC, mastering, and distribution for the media and entertainment industry, today announced the acquisition of Masterwords, a theatrical scripting service provider with a 40-year track record of delivering high-quality scripting services to Hollywood studios.

Eikon (group)

Jan

16th

2026

18:45

Events, Capital Investment, Artificial Intelligence, B2B Tag

Five Takeaways from JP Morgan Week 2026

Every January, thousands of pharma and biotech executives, analysts, and journalists descend on Union Square in San Francisco for a sprawling industry gathering that has less to do each year with its namesake, the JP Morgan Healthcare Conference at the Westin St Francis.

Pharmaphorum

Jan

9th

2026

12:29

B2B Tag

Eikon files for IPO after raising more than $1 billion to develop cancer-fighting drugs and the tools to make them

Eikon's leadership team includes a former research chief from two pharmaceutical giants, and the company's investor roster features some of the most prominent venture capital firms in life sciences.

The Business Journals

Dec

2nd

2025

18:30

B2B Tag

Appointments and advancements for Dec. 3, 2025

New hires and promotions in the biopharma industry, including: Adarx, ALK-Abello, Alkeus, Comanche, Eikon, Ernexa, Ovid, Palisade, Strand, Tacalyx, Trimtech, Ventyx.

BioWorld

Nov

4th

2025

23:51

CT_Monitor Company

Novel TLR Coagonist Combo Shows Responses in Stage IV NSCLC

Encouraging clinical activity was reported in patients with stage IV non–small cell lung cancer (NSCLC) who received ELK1001, an investigational toll-like receptor (TLR) 7/8 coagonist, plus pembrolizumab (Keytruda), according to a presentation on findings from the phase 2 TeLuRide-005 trial (NCT06246110) at the European Society for Medical Oncology (ESMO) Congress 2025 .1 The results indicated that the objective response rate (ORR) was 64% (95% CI, 41%-75%) among 50 evaluable patients.

Cancer Network (US)

Oct

28th

2025

17:50

Operational Challenges

Local tattoo shops impacted by Canadian tariffs, supplier stops shipment to U.S.

BUFFALO, N.Y. (WKBW) — For years, tattoo shops in Western New York relied on Eikon, a Canadian tattoo supply company. Eikon recently stopped shipping to the United States due to recent tariffs. "Eikon was a main place to order for a long time," said Jeffrey Bagneschi, of North Star Tattoo.

7 News WKBW

Oct

27th

2025

17:46

CT_Monitor Company

EIK1001 Plus Pembrolizumab/Chemo ORR 64% in 1L Stage IV NSCLC

Adding the toll-like receptor (TLR) 7/8 coagonist EIK1001 to pembrolizumab (Keytruda) and chemotherapy yielded an objective response rate (ORR) of 64% (95% CI, 49%-77%) as first-line therapy in 50 evaluable patients with stage IV non–small cell lung cancer (NSCLC), according to data from the phase 2 TeLuRide-005 trial (NCT06246110) that were presented at the 2025 ESMO Congress.

Targeted Oncology

Oct

20th

2025

16:45

CT_Monitor Company

Frontline EIK1001 Plus Chemoimmunotherapy Stimulates Antitumor Activity in Advanced NSCLC

The addition of the toll-like receptor (TLR) 7/8 coagonist EIK1001 to pembrolizumab (Keytruda) and chemotherapy produced an objective response rate (ORR) of 64% (95% CI, 49%-77%) as first-line therapy in 50 evaluable patients with stage IV non–small cell lung cancer (NSCLC), according to data from the phase 2 TeLuRide-005 trial (NCT06246110) that were presented at the 2025 ESMO Congress .

OncLive

Sep

16th

2025

13:54

Events

MLA calls for manufacturing strategy as conference panel highlights finance and funding challenges for sector

Speaking following a panel debate on finance and funding at the Eikon Exhibition Centre, Alliance party MLA for Lagan Valley Honeyford said the scale of innovation and ambition on display from local firms underlined why Northern Ireland cannot afford to fall behind international competitors.

Belfast News Letter

Sep

10th

2025

10:33

Climate Transition Risk, ESG Rating Divergence and Portfolio Performance: Evidence From Composite Scores and Climate‐Adjusted Factor Models

ABSTRACT This study investigates how ESG rating divergences and climate transition risks jointly influence portfolio performance. Using a newly constructed composite Environmental (E) score derived from principal component analysis (PCA) across three leading ESG providers (Eikon, RobecoSAM, Sustainalytics), we build industry‐adjusted portfolios for 389 US firms across 10 sectors, including agriculture and industrial sectors.

Wiley Online Library

EIKON Group's customers primarily consist of consumer electronics and entertainment Providers companies. Examples of EIKON Group's customers include The Walt Disney Company, Paramount Global and Apple.